3 CCR 713-1.28 - USE OF BENZODIAZEPINES

A. Basis: The basis for the Board's promulgation of these rules and regulations is sections 12-20-204(1), 12-240-106(1)(a), and 12-240-123, C.R.S. The specific statutory authority for the promulgation of this Rule is section 12-30-109(6), C.R.S.

B. Scope: The purpose of these rules and regulations is to implement rules required by section 12- 30-109(6), C.R.S., related to requirements for prescribing benzodiazepines to patients who have not previously prescribed benzodiazepines within the last twelve months.

A. Licensees must limit any prescription for a continuous benzodiazepine to a 30-day supply, for any patient who has not been prescribed a benzodiazepine in the last 12 months.

Prior to prescribing the second fill of a benzodiazepine for a condition that is not exempt under section 12-280-404(4) (a.5), C.R.S., a licensee must comply with the requirements of section 12-280-404(4), C.R.S.

C. The limitation stated in section (A) of this Rule does not apply to patients for whom licensees prescribe benzodiazepines for the following conditions:

1. Epilepsy;

2. A seizure, a seizure disorder, or a suspected seizure disorder;

3. Spasticity;

4. Alcohol withdrawal; or

5. A neurological condition, including a post-traumatic brain injury or catatonia.

D. These rules do not require or encourage abrupt discontinuation, limitation, or withdrawal of benzodiazepines. Licensees are expected to follow generally accepted standards of medical practice, based on an individual patient's needs, in tapering benzodiazepine prescriptions.

Notes

3 CCR 713-1.28

46 CR 12, June 25, 2023, effective 7/15/2023